BioMarin Pharmaceutical Acquires Zystor Therapeutics for $115,000,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=55f39173-fd7d-4d4e-bb40-e1f8f7dc457b&Preview=1 - Date
8/17/2010 - Company Name
Zystor Therapeutics - Mailing Address
10437 Innovation Drive Milwaukee, WI 53226-4838 - Company Description
ZyStor Therapeutics, Inc. is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs. - Website
http://www.zystor.com - Transaction Type
M&A - Transaction Amount
$115,000,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
Under the terms of the agreement, BioMarin acquired ZyStor for $22 million upfront and up to an additional $93 million if certain development, regulatory and commercial milestones are achieved.
